Targeting the lymph nodes with AAV is a specialized field, often focused on vaccine development, cancer immunotherapy, or treating lysosomal storage diseases. Unlike other organs, the challenge here is not just reaching the tissue, but specifically transducing Antigen-Presenting Cells (APCs) like dendritic cells and macrophages.

Quick Legend: Administration Routes

• SC (Subcutaneous) / ID (Intradermal): The most common route for lymph node targeting. The vector travels via the interstitial fluid into the afferent lymphatic vessels to reach the “draining” lymph node.
• IM (Intramuscular): Often used for vaccines. Some vector leaks into the lymphatic system to reach regional nodes.
• Intranodal (Direct): Ultrasound-guided injection directly into a lymph node. Highly efficient for that specific node but technically demanding.
• IV (Intravenous): Generally poor for lymph nodes as the vector is mostly sequestered by the liver and spleen.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV5	Dendritic Cells (DCs), Macrophages	SC / IM	The Vaccine Specialist. • Exhibits higher natural tropism for human and mouse dendritic cells than most other serotypes. • Excellent for inducing robust T-cell and B-cell immune responses against a transgene.
AAV1	Dendritic Cells, Myocytes	SC / IM	Robust Immune Induction. • Frequently used in genetic immunization (vaccines). • Highly efficient at transducing APCs in the skin and muscle that then migrate to the lymph nodes.
AAV9	Stroma, Some Immune Cells	SC / IV	Broad & Diffuse. • Known for its ability to cross endothelial barriers. While it can reach lymph nodes, it is less “immune-cell specific” than AAV5 or AAV1.
AAV8	Hepatocytes, Some APCs	SC	High Efficiency. • While primarily a liver vector, AAV8 has shown high transduction of the subcapsular sinus macrophages in lymph nodes following subcutaneous delivery.
AAV2	APCs (Low efficiency)	Direct	The Reference. • Generally has lower transduction of immune cells compared to AAV1/5/6 unless delivered at extremely high titers.

---

2. Engineered & Synthetic Capsids

These are designed to enhance uptake by professional immune cells or shield the virus from neutralizing antibodies.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV6.2	Dendritic Cells, Airway Epithelium	SC / IN	A modified AAV6 that shows improved stability and higher transduction of dendritic cells, making it a strong candidate for immunotherapy.
AAV-DJ	Broad (including APCs)	SC / Direct	Synthetic Hybrid. • Outperforms most natural serotypes in in vitro DC transduction. • Useful for ex-vivo loading of dendritic cells before re-injecting them into the patient.
AAV-S663V	Antigen-Presenting Cells	IM / SC	The Proteasome Dodger. • A capsid mutation that prevents proteasomal degradation. • Increases the amount of intact virus reaching the lymph node, significantly boosting the immune response at lower doses.

---

3. Tropism by Target Cell Type

If your goal is a specific immunological outcome, start here:

• Dendritic Cells (for Vaccines): AAV5 or AAV1.
• Macrophages (Subcapsular Sinus): AAV8.
• Global Lymphatic Drainage: AAV9 (via SC injection).
• T-Cells / B-Cells: Generally difficult to transduce directly with AAV; usually targeted indirectly via APCs or through Ex-Vivo transduction.

---

Critical Factor: The “Double-Edged Sword” of Immunity

In most AAV therapies (like for Heart or Liver), the immune response is an enemy. In Lymph Node targeting, it is often the goal.

1. Capsid vs. Transgene: When targeting lymph nodes for a vaccine, you want the body to react to the transgene (the medicine) but not necessarily the capsid (the delivery truck).
2. The Solution:
   • Promoters: Use a strong ubiquitous promoter like CAG or CMV if you want maximum immune activation.
   • TLR9 Signaling: AAV naturally triggers TLR9 in immune cells. Some engineered vectors increase this “danger signal” to act as a built-in adjuvant for vaccines.